Published in the European Heart Journal, an analysis of the SELECT clinical trial reveals that semaglutide reduces major adverse cardiovascular events by 20% in overweight or obese patients without diabetes.
Unraveling the SELECT Trial Data: Beyond the Scale
Traditionally used as a treatment for weight loss, semaglutide belongs to a class of medications known as glucagon-like peptide-1 receptor agonists (GLP-1 RAs). When the SELECT (Efectos de la semaglutida en los resultados cardiovasculares en personas con sobrepeso u obesidad) trial enrolled 17,604 participants, its objective was to observe whether the drug could mitigate cardiovascular events in non-diabetic individuals struggling with excess weight. Half of the cohort received the active pharmacological intervention, while the other half received a matched placebo.
During the two-year longitudinal evaluation, investigators tracked multiple metabolic biomarkers, including body weight, waist circumference, systemic blood pressure, lipid profiles, renal function, and inflammatory markers. Participants administered semaglutide experienced reductions in body mass and waist circumference alongside improvements in metabolic panels. However, statistical modeling exposed a critical physiological gap: these known risk factor modifications accounted for no more than half of the observed 20% drop in heart attacks, strokes, and cardiovascular deaths.
"Whether we combine all the risk factors or analyze subsets of them, no more than half of the reduction in heart disease could be explained by the changes in these factors," Colhoun explained.
In Plain English: The Clinical Takeaway
- Beyond Weight Loss: While losing pounds helps the heart, semaglutide appears to protect the cardiovascular system through separate, yet-to-be-fully-understood biological pathways.
- The 20% Reduction: Large-scale clinical trial data confirms a clear decrease in serious heart events, even for patients who do not carry a diagnosis of type 2 diabetes.
- Direct Vascular Impact: Researchers hypothesize that the drug may directly reduce inflammation within blood vessels and the heart muscle itself.
Potential Mechanisms: Direct Vascular and Anti-Inflammatory Action
Because traditional metabolic markers fail to account for the full therapeutic effect, clinical researchers are turning their attention to alternative pathways. The mechanism of action for GLP-1 receptor agonists extends beyond glycemic control. It has been proposed that there are direct effects on the heart muscle or the lining of blood vessels.
Among the leading hypotheses being investigated are anti-inflammatory properties that are not fully reflected in the risk factors measured in the trial.
| Trial Parameter | Clinical Detail |
|---|---|
| Total Participants (N) | 17,604 patients |
| Intervention Class | Glucagon-like peptide-1 (GLP-1) receptor agonist vs. Placebo |
| Observed Cardiovascular Risk Reduction | 20% decrease in major adverse cardiovascular events |
| Explained by Traditional Risk Factors | No more than half accounted for by weight/waist changes |
While prior clinical trials established the cardiovascular benefits of GLP-1 receptor agonists primarily in populations with established type 2 diabetes, the SELECT trial marks a critical pivot. It provides evidence that these benefits translate to individuals with overweight or obesity in the absence of diabetes. Consequently, these results suggest that semaglutide should be considered a drug to reduce cardiovascular diseases and not only for weight loss.
Contraindications & When to Consult a Doctor
References
- European Heart Journal: Studies on Semaglutide and Cardiovascular Outcomes from the SELECT Trial.
